初级中枢神经系统淋巴瘤的免疫化疗或单独化疗:国家癌症数据库分析
Thomas A Ollila1,2, Rashida Taher2, Prashanth Moku1
1Department of Medicine, Alpert Medical School of Brown University, Providence, RI.
Blood advances
|July 17, 2023
概括
利图西马布免疫疗法改善了初级中枢神经系统淋巴瘤 (PCNSL) 患者的生存率. 然而,它的使用因人口统计和医院而异,老年患者的益处较小.
科学领域:
- 神经瘤学神经瘤学
- 免疫疗法研究研究
- 临床试验分析临床试验分析
背景情况:
- 主要中枢神经系统淋巴瘤 (PCNSL) 治疗疗效仍在争论中,特别是由于中枢神经系统透率有限,Rituximab的作用.
- 国家癌症数据库自2013年以来一直区分化疗和免疫疗法,而rituximab是唯一的标准前线免疫疗法.
研究的目的:
- 研究影响PCNSL患者接受免疫治疗的因素.
- 为了比较接受免疫治疗的患者和没有接受免疫治疗的患者之间的整体存活率 (OS).
主要方法:
- 关于相对风险和随机拦截的多变量回归模型,以分析与免疫治疗接收相关的因素.
- 1:1倾向性得分匹配,以创建可比的生存分析队列.
- 分析了在2013年至2018年期间诊断的4691名PCNSL患者,其中2830人与生存相匹配.
主要成果:
- 免疫疗法使用率从45% (2013) 增加到76% (2018).
- 与减少免疫疗法使用相关的因素包括男性性别,黑人/西班牙裔种族,艾滋病毒+状态,体积较小的医院和早期诊断年份.
- 接受免疫疗法与明显改善的生存状况有关 (HR 0.75;95% CI 0.67-0.83).
- 与75岁以上 (HR 0.87) 患者相比,在≤75岁 (HR 0.71) 的患者中,生存益处更为明显.
结论:
- 这些发现支持在PCNSL治疗中使用Rituximab的趋势日益增加.
- 对于接受免疫治疗的老年PCNSL患者,建议采用微妙的方法.
- 对优化针对特定患者群体的免疫疗法的进一步研究是有必要的.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.2K
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
15.9K
相关概念视频
01:27Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K